Wordt geladen...
Dual Antiplatelet Therapy Beyond 90 Days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial
BACKGROUND: The safety and efficacy of dual antiplatelet use for symptomatic intracranial atherosclerosis beyond 90 days is unknown. Data from SAMMPRIS was used to determine if dual antiplatelet therapy (DAPT) beyond 90 days impacted the risk of ischemic stroke and hemorrhage. METHODS: This post hoc...
Bewaard in:
| Gepubliceerd in: | J Stroke Cerebrovasc Dis |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7686095/ https://ncbi.nlm.nih.gov/pubmed/32992190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2020.105254 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|